

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 18 U.S.C. §208(b)(3)

Ronald Bukowski, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: June 2, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to new drug application (NDA) 21-986, proposed trade name Sprycel (dasatinib) tablets (BMS-354825), sponsored by Bristol Myers Squibb, with the proposed indications for (1) treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia with resistance to prior therapy including imatinib, and (2) the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia and lymphoid blast chronic myeloid leukemia with resistance or intolerance to prior therapy, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Consulting	Competitor	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

/s/
Signature of SGE

4-20-06
Date